SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 455 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,664,481 | +56.7% | 30,230 | +48.0% | 0.01% | +66.7% |
| Q2 2023 | $2,339,071 | -89.3% | 20,425 | -87.2% | 0.00% | -90.3% |
| Q1 2023 | $21,915,108 | +350.1% | 159,001 | +323.1% | 0.03% | +342.9% |
| Q4 2022 | $4,869,228 | -99.9% | 37,577 | -46.1% | 0.01% | -12.5% |
| Q2 2022 | $5,226,511,000 | -48.9% | 69,724 | -46.8% | 0.01% | -42.9% |
| Q1 2022 | $10,230,048,000 | -20.9% | 130,953 | -8.8% | 0.01% | -22.2% |
| Q4 2021 | $12,931,990,000 | +129.3% | 143,609 | +135.5% | 0.02% | +125.0% |
| Q3 2021 | $5,639,800,000 | +97.4% | 60,984 | +65.9% | 0.01% | +100.0% |
| Q2 2021 | $2,857,023,000 | -11.8% | 36,751 | -15.4% | 0.00% | -20.0% |
| Q1 2021 | $3,238,254,000 | -28.4% | 43,449 | +63.9% | 0.01% | -37.5% |
| Q4 2020 | $4,519,690,000 | +34.1% | 26,510 | +10.5% | 0.01% | +60.0% |
| Q3 2020 | $3,370,460,000 | -37.0% | 24,001 | -28.0% | 0.01% | -44.4% |
| Q2 2020 | $5,348,141,000 | +41.4% | 33,355 | -13.8% | 0.01% | +12.5% |
| Q1 2020 | $3,783,188,000 | +5.4% | 38,675 | +39.1% | 0.01% | +14.3% |
| Q4 2019 | $3,588,990,000 | +98.0% | 27,813 | +15.6% | 0.01% | +133.3% |
| Q3 2019 | $1,812,425,000 | +59.3% | 24,063 | +221.3% | 0.00% | +50.0% |
| Q2 2019 | $1,137,954,000 | +256.8% | 7,489 | +179.9% | 0.00% | +100.0% |
| Q1 2019 | $318,952,000 | +13.4% | 2,676 | +3.8% | 0.00% | 0.0% |
| Q4 2018 | $281,337,000 | -76.5% | 2,578 | -65.3% | 0.00% | -50.0% |
| Q3 2018 | $1,198,889,000 | +308.6% | 7,423 | +234.4% | 0.00% | – |
| Q2 2018 | $293,440,000 | -77.5% | 2,220 | -87.4% | 0.00% | -100.0% |
| Q1 2018 | $1,302,650,000 | +49.4% | 17,582 | +12.2% | 0.00% | 0.0% |
| Q4 2017 | $872,157,000 | +183.1% | 15,675 | +130.8% | 0.00% | +100.0% |
| Q3 2017 | $308,085,000 | +40.8% | 6,792 | +4.7% | 0.00% | 0.0% |
| Q2 2017 | $218,744,000 | +524.7% | 6,489 | +448.5% | 0.00% | – |
| Q1 2017 | $35,017,000 | -33.0% | 1,183 | -37.9% | 0.00% | – |
| Q4 2016 | $52,227,000 | -76.0% | 1,904 | -46.2% | 0.00% | -100.0% |
| Q3 2016 | $217,453,000 | +589.0% | 3,541 | +114.0% | 0.00% | – |
| Q2 2016 | $31,561,000 | -91.4% | 1,655 | -82.7% | 0.00% | -100.0% |
| Q4 2015 | $368,824,000 | +33.3% | 9,560 | +10.9% | 0.00% | 0.0% |
| Q3 2015 | $276,724,000 | +163.7% | 8,618 | +149.9% | 0.00% | – |
| Q2 2015 | $104,953,000 | +711.4% | 3,449 | +254.1% | 0.00% | – |
| Q1 2015 | $12,935,000 | -73.9% | 974 | -58.5% | 0.00% | – |
| Q3 2014 | $49,480,000 | +458.4% | 2,345 | +439.1% | 0.00% | – |
| Q4 2013 | $8,861,000 | -97.9% | 435 | -95.2% | 0.00% | – |
| Q3 2013 | $425,353,000 | -12.4% | 9,006 | -29.4% | 0.00% | – |
| Q2 2013 | $485,467,000 | – | 12,762 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
| Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
| Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
| Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
| Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
| Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
| ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
| Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
| Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
| GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |